{
  "ticker": "NSB",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02972626",
  "id": "02972626",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250725",
  "time": "0919",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250725/pdf/06m46ydyg2w6qn.pdf",
  "summary": "- **Key Appointment**: Dr. Catherine Cole appointed as Chief Medical Officer (CMO), effective immediately.  \n- **Clinical Focus**: Dr. Cole\u2019s expertise to support the **Special Access Scheme (SAS) program for Fistulas in Crohn\u2019s**, with interim results expected later in 2025.  \n- **Strategic Implication**: Strengthens leadership for regulatory and clinical trial execution, particularly in immune-mediated disorders (e.g., Crohn\u2019s, GVHD).  \n\n*No material financial, capital, or trading-specific information identified.*",
  "usage": {
    "prompt_tokens": 1460,
    "completion_tokens": 112,
    "total_tokens": 1572,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-24T23:39:16.821389"
}